Dr. Nancy S. Reau discussed findings from a study comparing the efficacy of mycophenolate mofetil and azathioprine for autoimmune hepatitis at the ACG Annual Scientific Meeting. The study emphasized that azathioprine remains an effective treatment for many patients despite the results showing potential benefits of mycophenolate mofetil. The data were presented at the meeting in Philadelphia. Dr. Reau, who serves as the Richard B. Capps Chair of Hepatology at Rush University, highlighted the importance of cautious interpretation of the study’s findings. The study was a systematic review and meta-analysis comparing the two treatment options for autoimmune hepatitis.
Source link
Treating autoimmune hepatitis with mycophenolate ‘still a cautionary tale’
